The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Savona, Professor of Medicine and Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, provides impressions of the Phase III ASCEMBL study investigating asciminib versus bosutinib in patients with chronic myeloid leukemia (CML) presented at ASH 2020
Tags: ASH Conference CoverageLeukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)
Published: 09 December 2020
Bo Gamble, on the most important critical success factors when adopting a new payment model
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, offers opinion on the most important critical success factors when adopting a new payment model
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, offers opinion on the most important critical success factors when ...
Alti Rahman, MHA\MBA, CSSBB, reflects on social determinants of health in cancer care
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, reflects on social determinants of health and considers how an oncology practice can remain efficient and sensitive to patients who have just received a cancer diagnosis
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, reflects on social determinants of health and considers how an oncology practice ...
Bo Gamble, discusses the impact of consolidation on the delivery of cancer care
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, discusses the impact of consolidation on the delivery of cancer care and on alterative payment models (APMs)
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, discusses the impact of consolidation on the delivery of cancer ...
Bo Gamble, speculates on the future of alternative payment models (APMs)
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, speculates on the future of alternative payment models (APMs) and explains how a practice can determine which APMs are most appropriate to pursue
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, speculates on the future of alternative payment models (APMs) and ...
Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, offers advice to oncology practices looking to succeed in today's landscape of cancer care
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, offers advice to oncology practices looking to succeed in today's landscape of ...
Alti Rahman, MHA\MBA, CSSBB, regarding the impact of consolidation on the delivery of cancer care
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, regarding the impact of consolidation on the delivery of cancer care
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, regarding the impact of consolidation on the delivery of cancer care
Bo Gamble, considers how value & quality may vary across community oncology practices
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, considers how the concepts of value and quality may vary across community oncology practices
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, considers how the concepts of value and quality may vary ...
Bo Gamble, compares and contrasts the definition of value and quality as it relates to cancer care
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, compares and contrasts the definition of value and quality as it relates to cancer care
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, compares and contrasts the definition of value and quality as ...
Alti Rahman, MHA\MBA, CSSBB, considers how oncology practices can reduce costs & maximize savings
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, discusses some of the best practices for oncology practices to help reduce costs and maximize savings
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, discusses some of the best practices for oncology practices to help reduce ...
Alti Rahman, MHA\MBA, CSSBB, provides perspective on the challenges facing oncology practices
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, provides perspective on some of the biggest challenges currently facing oncology practices
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, provides perspective on some of the biggest challenges currently facing oncology practices
Bo Gamble, on the most important critical success factors when adopting a new payment model
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, offers opinion on the most important critical success factors when adopting a new payment model
Alti Rahman, MHA\MBA, CSSBB, provides perspective on the challenges facing oncology practices
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, provides perspective on some of the biggest challenges currently facing oncology practices
Alti Rahman, MHA\MBA, CSSBB, considers how oncology practices can reduce costs & maximize savings
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, discusses some of the best practices for oncology practices to help reduce costs and maximize savings
Bo Gamble, compares and contrasts the definition of value and quality as it relates to cancer care
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, compares and contrasts the definition of value and quality as it relates to cancer care
Bo Gamble, considers how value & quality may vary across community oncology practices
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, considers how the concepts of value and quality may vary across community oncology practices
Alti Rahman, MHA\MBA, CSSBB, regarding the impact of consolidation on the delivery of cancer care
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, regarding the impact of consolidation on the delivery of cancer care
Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, offers advice to oncology practices looking to succeed in today's landscape of cancer care
Bo Gamble, speculates on the future of alternative payment models (APMs)
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, speculates on the future of alternative payment models (APMs) and explains how a practice can determine which APMs are most appropriate to pursue
Bo Gamble, discusses the impact of consolidation on the delivery of cancer care
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, discusses the impact of consolidation on the delivery of cancer care and on alterative payment models (APMs)
Alti Rahman, MHA\MBA, CSSBB, reflects on social determinants of health in cancer care
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, reflects on social determinants of health and considers how an oncology practice can remain efficient and sensitive to patients who have just received a cancer diagnosis
Johnetta Blakely, MD, offers an example of how HEOR has impacted cancer care at Tennessee Oncology
Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, offers a case example of how real-world evidence and health economics outcomes research (HEOR) have made an impact on the quality and cost of cancer care at Tennessee Oncology
Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists
Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, considers the progress being made at the community level in providing cancer patients with access to innovative therapies and quality of care while reducing cost
Johnetta Blakely, MD, explains the role of HEOR as it contributes to value-based care
Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, explains the role of health economics outcomes research (HEOR) as it contributes to value-based care
Johnetta Blakely, MD, considers how HEOR data influences payer decisions
Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, considers how health economics and outcomes research (HEOR) data influences payer decisions
Johnetta Blakely, MD, elaborates on how HEOR may be used in conjunction with real-world evidence
Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, elaborates on how health economics outcomes research (HEOR) may be used in conjunction with artificial intelligence and/or real-world evidence
Sara Riordan, MS, CGC, regarding the significance of biomarker testing in early-stage cancer
Sara Riordan, Senior Director, Medical Education, OncoCyte Corporation, President, National Society of Genetic Counselors, offers opinion on why it is important to conduct genetic signature and biomarker testing in early-stage cancer patients
Sara Riordan, MS, CGC, on the role of genetic counselors as part of a multidisciplinary cancer team
Sara Riordan, Senior Director, Medical Education, OncoCyte Corporation, President, National Society of Genetic Counselors, discusses the role of genetic counselors as part of the multidisciplinary cancer team
Jonathan E. Levitt, Esq., discusses the state of payer mandates for white / brown bagging
Jonathan E. Levitt, Esq., Co-Founding Partner, Frier Levitt, discusses the state of payer mandates for white bagging and brown bagging
Jonathan E. Levitt, Esq., explains how DIR fees impact practice costs and efficiencies
Jonathan E. Levitt, Esq., Co-Founding Partner, Frier Levitt, explains how DIR fees impact practice costs and efficiencies
Jonathan E. Levitt, Esq., on the experience of hem/onc groups unable to enter into a PBM network
Jonathan E. Levitt, Esq., Co-Founding Partner, Frier Levitt, considers the experience of hematology/oncology groups who are unable to enter into a PBM network
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.